Deciphering tau phosphorylation and Abeta/tau strain interactions in Alzheimer’s pathogenesis

Abstract
The clinical symptoms of Alzheimer disease (AD) dementia occur downstream of pathological deposition
of Aβ peptides in extracellular cored-neuritic plaques and aggregated tau protein in intracellular neurofibrillary
tangles (NFT) in the brain. Since deposition of Aβ precedes tauopathy in early-onset familial AD (fAD), it is
accepted that Aβ can trigger tau misfolding into NFT, initiating a cascade of cumulative pathology that
progressively leads to dementia. In sporadic AD, the coincident deposition of Aβ appears to correlate with tau
misfolding and the severity of NFT pathology. Collectively, these findings suggest that Aβ deposition can
exacerbate tau misfolding and NFT formation leading to cognitive deficits and dementia. However, the underlying
mechanisms and characteristics of Aβ and tau that synergize resulting in NFT pathology and pathological
sequelae is still unclear. Our proposal is designed to provide experimental insights into the individual contribution
of tau (Aim 1) and Aβ (Aim 2) in driving Aβ-tau synergy in mouse models of AD.
Evidence suggests that a major mechanism by which Aβ synergizes with tau misfolding involves the
hyper-phosphorylation of tau. A recent study of AD patients that quantitatively mapped the progressive
emergence of phosphorylated epitopes in tau identified 19 Ser/Thr residues that are most frequently
phosphorylated in individuals that exhibit concurrent Aβ pathology. The main objective in Aim 1 is to dissect the
contribution of these phosphorylation events in the misfolding and aggregation of tau that occurs in the presence
of concurrent Aβ pathology. Using AAV technology, we have the capability to generate and express a large
number of tau phospho-mimetic variants in APP TgCRND8 mice. Using this mouse model, in Aim 1 we propose
a broad study to systematically dissect the phosphorylation events that drive tau misfolding and NFT formation
in the presence of Aβ.
Over many years of research, our laboratories have created mouse models that exhibit a spectrum of Aβ
pathologies, including mice that develop primarily diffuse Aβ pathology and mice that primarily develop cored-
neuritic pathology. Given that there are questions regarding the type of Aβ pathology that underlie Aβ-tau
synergy, in Aim 2, we propose to use our AAV approach to examine Aβ-tau interactions in this diverse collection
of APP transgenic models that exhibit different types of Aβ pathology. Additionally, in Aim 2, we will use
pharmacologics and inducible APP models to examine the role of newly-made soluble Aβ vs long-lived insoluble
Aβ in tau phosphorylation/aggregation process. Phospho-proteomic analysis will help us determine the
relationship of different types of Aβ to the resulting tau phosphorylation profile.
Collectively, this work will improve our understanding of the Aβ-driven phosphorylation cascade that
appears to promote tau misfolding and aggregation into NFT.

Grant Number: 5R01AG078734-04
NIH Institute/Center: NIH
Principal Investigator: PARAMITA CHAKRABARTY